Anti-factor IXa/X bispecific antibody (ACE910): Hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 2, 2014, Pages 206-213

  Muto, A ^a   Yoshihashi, K ^a   Takeda, M ^a   Kitazawa, T ^a   Soeda, T ^a   Igawa, T ^a   Sakamoto, Y ^a   Haraya, K ^a   Kawabe, Y ^a   Shima, M ^b   Yoshioka, A ^b   Hattori, K ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Antibodies, catalytic; Factor VIII; Hemophilia A; Hemostasis; Therapeutics

Indexed keywords

ACE 910; BISPECIFIC ANTIBODY; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 9A; HEMOGLOBIN; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BOLUS INJECTION; CONTROLLED STUDY; CROSS REACTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEMOPHILIA A; HEMOSTASIS; IN VIVO STUDY; MACACA FASCICULARIS; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROPHYLAXIS; RAT; SIMULATION; SUPPLEMENTATION; ANIMAL; CHO CELL LINE; CRICETULUS; DISEASE MODEL; HAMSTER; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; MALE;

ANIMALS; ANTIBODIES; CHO CELLS; CRICETINAE; CRICETULUS; CROSS REACTIONS; DISEASE MODELS, ANIMAL; FACTOR IXA; FACTOR X; HEK293 CELLS; HEMOPHILIA A; HEMOSTASIS; HUMANS; MACACA FASCICULARIS; MALE;

EID: 84893537691     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12474     Document Type: Article

References (19)

1. Den Uijl IE, Fischer K, van der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia 2009; 15: 83-90.
2. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379: 1447-56.
3. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
4. Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
5. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
6. Oldenburg J. Prophylaxis in bleeding disorders. Thromb Res 2011; 127: S14-17.
7. Ragni M, Fogarty P, Josephson N, Neff A, Raffini L, Kessler C. Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres. Haemophilia 2012; 18: 63-8.
8. Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, Yoshihashi K, Okuyama-Nishida Y, Saito H, Tsunoda H, Suzuki T, Adachi H, Miyazaki T, Ishii S, Kamata-Sakurai M, Iida T, Harada A, Esaki K, Funaki M, Moriyama C. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18: 1570-4.
9. Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, Yoshihashi K, Harada A, Funaki M, Haraya K, Tachibana T, Suzuki S, Esaki K, Nabuchi Y, Hattori K. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS ONE 2013; 8: e57479.
10. Den Uijl IE, Mauser Bunschoten EP, Roosendaal G, Schutgens RE, Biesma DH, Grobbee DE, Fischer K. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia 2011; 17: 849-53.
11. Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia 2008; 14: 83-92.
12. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, Street A. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
13. Lillicrap D. The future of hemostasis management. Pediatr Blood Cancer 2013; 60: S44-7.
14. Pipe SW. The hope and reality of long-acting hemophilia products. Am J Hematol 2012; 87: S33-9.
15. Collins PW. Personalized prophylaxis. Haemophilia 2012; 18: 131-5.
16. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 2011; 3: 61-6.
17. Dong J, Salinger D, Endres C, Gibbs J, Hsu C, Stouch B, Hurh E, Gibbs M. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 2011; 50: 131-42.
18. Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J, Gupta S, Herzyk D, Hurst C, Ivens IA, Kawabata T, Maier C, Mounho B, Rup B, Shankar G, Smith H, Thomas P, Wierda D. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol 2009; 54: 164-82.
19. Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K. Engineering the variable region of therapeutic IgG antibodies. MAbs 2011; 3: 243-52.